載入...
Optimum Use of Acute Treatments for Hereditary Angioedema: Evidence-Based Expert Consensus
Acute treatment of hereditary angioedema due to C1 inhibitor deficiency has become available in the last 10 years and has greatly improved patients’ quality of life. Two plasma-derived C1 inhibitors (Berinert and Cinryze), a recombinant C1 inhibitor (Ruconest/Conestat alpha), a kallikrein inhibitor...
Na minha lista:
| 發表在: | Front Med (Lausanne) |
|---|---|
| 主要作者: | |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Frontiers Media S.A.
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5857575/ https://ncbi.nlm.nih.gov/pubmed/29594115 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmed.2017.00245 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|